LisenID and ChristianaCare team up in a research collaboration

Wilmington, Del. — July 4th, 2026 — Lisen Imprinting Diagnostics (LisenID), a precision diagnostics company pioneering the clinical application of Loss of Imprinting (LOI) as an early molecular biomarker for cancer, announced on June 15th 2026 a research collaboration with ChristianaCare’s Cawley Center for Translational Cancer Research to evaluate its proprietary QCIGISH (Quantitative Chromogenic Imprinted Gene […]

Read More